NURS 6521 Week 11 Assignment - Off-Label Drug Use in Pediatrics

Introduction Off-label drug use is defined as using a medication for a condition that is not included in the approved FDA labeling for that drug. The use of off-label drugs in children is typically due to the treatment with drugs licensed by the FDA being suboptimal or not suitable as a treatment option. There are many medications that are relevant and beneficial but are not licensed by the FDA for use in the pediatric population. The purpose of this assignment is to explore the circumstances of off-label drug use in pediatrics and describe safety strategies for their use and dosage. Off-Label Drug Use in Pediatrics There are several circumstances in which children are prescribed drugs for off-label use. One significant circumstance in which children are prescribed drugs for off-label use is the absence of safe and approved treatment options for a particular condition. For example, although enalapril is FDA approved for the treatment of hypertension in children, it is commonly used off- label to treat heart failure in pediatric patients (Allen et al., 2018). Other circumstances in which children are prescribed drugs for off-label use include when standard treatment options have failed, the safety and effectiveness of the medication for the off-label patient groups or conditions have been proven, and when there is a shortage of alternative types of therapy for particular age groups. The benefits of the use of off-label drugs may justify their use outside of the preapproved indications. Safety Strategies To make off-label use and dosage of drugs safer for children from infancy to adolescence, the provider must perform an assessment of the child, then assess the risks and benefits of the medication before prescribing the drug to the patient. Children are exposed to the risk of lack of efficacy, unknown toxicity, and harm without a positive assessment of risks and benefits (Zanden et al., 2021). The patient should be monitored closely for adverse effects of the medications. The patient’s vital signs and baseline tests should be measured. Laboratory tests may also be required intermittently. Also, more clinical trials and studies of medications for their off-label use in the pediatric population should be conducted. Before the pediatric program was initiated by the FDA, approximately 20% of drugs that were FDA-approved were labeled for use in the pediatric population (U.S. Food and Drug Administration, 2016). One off-level drug that requires extra care and attention when used in pediatrics is fentanyl. Fentanyl is commonly used in children admitted to ICU as a sedative and analgesic agent. By both age and indication, the off-label use of fentanyl is associated with an increased risk for respiratory depression, particularly in infants (Oshikoya et al., 2019). Thus, extra care and attention are imperative when using fentanyl in the pediatric population. Conclusion It is vital that off-label drugs be used safely and efficiently. Strategies to make off-label use and dosage of drugs safer for the pediatric population should be implemented as the patient’s safety is the top priority. To advance the knowledge on the use of off-label drugs, more research on the off-label use of drugs in pediatrics should be conducted to prove the safety and efficiency of use. Documentation of adverse effects and the efficiency of the medication by the provider is crucial to clinical evidence. References Allen, H. C., Garbe, M. C., Lees, J., Aziz, N., Chaaban, H., Miller, J. L., Johnson, P., & DeLeon, S. (2018). Off-label medication use in children, more common than we think: A systematic review of the literature. The Journal of the Oklahoma State Medical Association, 111(8), 776–783. Oshikoya, K. A., Wharton, G. T., Avant, D., Van Driest, S. L., Fenn, N. E., Lardieri, A. B., Doe, E., Sood, B. G., Taketomo, C., Lieu, P., Yen, L., & McMahon, A. (2019). Serious adverse events associated with off-label use of azithromycin or fentanyl in children in intensive care units: A retrospective chart review. Pediatric Drugs, 21(1), 47–58. U.S. Food and Drug Administration. (2016). Drug Research and Children. children Zanden, T. M., Mooij, M. G., Vet, N. J., Neubert, A., Rascher, W., Lagler, F. B., Male, C., Grytli, H., Halvorsen, T., Hoog, M., & Wildt, S. N. (2021). Benefit‐risk assessment of off‐label drug use in children: The bravo framework. Clinical Pharmacology &Amp; Therapeutics, 110(4), 952–965.